


## NEUROTROPHIN ANTAGONIST COMPOSITIONS

## ABSTRACT OF THE INVENTION

5 A pharmaceutical composition comprising a compound of Formula I



wherein R<sup>1</sup> is selected from, *inter alia*, alkyl, aryl-loweralkyl, heterocycle-loweralkyl,  
 10 loweralkyl-carbonate; optionally substituted amino; benzimidaz-2-yl; optionally  
 substituted phenyl; loweralkyl-(R<sup>5</sup>)(R<sup>6</sup>) wherein one of R<sup>5</sup> and R<sup>6</sup> is selected from H and  
 and the other is selected from carboxy, carboxy-loweralkyl and loweralkoxycarbonyl;  
 NHCH<sub>2</sub>CH<sub>2</sub>OX wherein X represents an *in vivo* hydrolyzable ester; and R<sup>2</sup> and R<sup>3</sup> are  
 independently selected from H, NO<sub>2</sub>, halo, di(loweralkyl)amino, cyano, C(O)OH, phenyl-  
 15 S-, loweralkyl, and Z(O)OR<sup>7</sup> wherein Z is selected from C and S and R<sup>7</sup> is selected from  
 H, loweralkylamino and arylamino; or pharmaceutically acceptable salts or certain *in vivo*  
 hydrolyzable esters or amides thereof, in an amount effective to inhibit neurotrophin-  
 mediated activity, and a suitable carrier, is described.

The compositions are useful to inhibit undesirable neurotrophin-mediated activity  
 20 such as the neurite outgrowth that occurs in some neurodegenerative disease states.